NALF1: A Potential Drug Target and Biomarker for Diseases (G728215)

Target Name: NALF1

NCBI ID: G728215

NALF1

NALF1: A Potential Drug Target and Biomarker for Diseases

NALF1 (Nucleases-伪-LIGHT-Fam155A), a protein that belongs to the family of nucleotideases, is a key regulator of DNA repair and replication in various cell types. It is expressed in various tissues and organs, including the brain, heart, liver, and stem cells. NALF1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The NALF1 protein is composed of 155 amino acid residues and has a calculated molecular weight of 19.9 kDa. It is a cytoplasmic protein that is predominantly localized to the endoplasmic reticulum (ER) and is also expressed in the nuclear envelope (NE) of certain cells. NALF1 is a transmembrane protein that is covered by the plasma membrane and the endoplasmic reticulum membrane. It has a hydrophobic domain that is involved in the formation of a transmembrane domain and a cytoplasmic domain that is involved in the formation of a cytoplasmic tail.

NALF1 is involved in various cellular processes, including DNA replication, repair, and transcription. It is a critical regulator of the DNA damage repair pathway, which is responsible for repairing damage to DNA that can occur due to various factors, such as mutations, UV radiation, and radiation therapy. NALF1 is also involved in the regulation of DNA replication, which is critical for the growth and development of cells.

In neurodegenerative diseases, NALF1 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. NALF1 has been shown to be expressed in the brains of individuals with these disorders and has been linked to the pathogenesis of these diseases.

In addition to its role in neurodegenerative diseases, NALF1 has also been implicated in the development and progression of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. NALF1 has been shown to be expressed in the peripheral tissues of individuals with these disorders and has been linked to the pathogenesis of these diseases.

As a potential drug target, NALF1 has been the focus of research in recent years. NALF1 has been shown to be involved in various signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation. NALF1 has also been shown to be involved in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and function.

In addition to its potential as a drug target, NALF1 has also been identified as a potential biomarker for various diseases. NALF1 has been shown to be involved in the regulation of cellular processes that are critical for disease development, including neurodegenerative diseases and autoimmune disorders. Additionally, NALF1 has been shown to be involved in the regulation of cellular processes that are critical for cancer development, including the regulation of apoptosis.

In conclusion, NALF1 is a key regulator of DNA repair and replication in various cell types and has been implicated in the development and progression of various diseases, including neurodegenerative diseases and autoimmune disorders. As a potential drug target and biomarker, NALF1 is a promising target for the development of new therapies for these diseases. Further research is needed to fully understand the role of NALF1 in these diseases and to develop effective treatments.

Protein Name: NALCN Channel Auxiliary Factor 1

Functions: Auxillary component of the NALCN sodium channel complex, a channel that regulates the resting membrane potential and controls neuronal excitability

The "NALF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NALF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets